A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00421135

Enrollment

Registered

2007-01-11

Start date

2006-02-28

Completion date

2007-10-31

Last updated

2009-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Cancer

Brief summary

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced cancer.

Interventions

DRUGZIO-201

ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Metastatic and /or unresectable disease state after previous standard chemotherapy

Design outcomes

Primary

Measure	Time frame
toxicities	6 months

Secondary

Measure	Time frame
pharmacokinetics	6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026